[{"address1": "2401 4th Avenue", "address2": "Suite 1050", "city": "Seattle", "state": "WA", "zip": "98121", "country": "United States", "phone": "206 838 0500", "fax": "206 838 0503", "website": "https://www.aptevotherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Mr. Marvin L. White", "age": 61, "title": "President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 841394, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey G. Lamothe CA", "age": 57, "title": "Executive VP & COO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 722511, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. SoYoung  Kwon J.D., LL.M.", "age": 54, "title": "Senior VP, General Counsel, Business Development & Corporate Affairs", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 639366, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Daphne L. Taylor", "age": 57, "title": "Senior VP & CFO", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dirk  Huebner M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.04, "open": 5.04, "dayLow": 4.93, "dayHigh": 5.5893, "regularMarketPreviousClose": 5.04, "regularMarketOpen": 5.04, "regularMarketDayLow": 4.93, "regularMarketDayHigh": 5.5893, "beta": 4.912, "forwardPE": -0.51619047, "volume": 139210, "regularMarketVolume": 139210, "averageVolume": 89372, "averageVolume10days": 499559, "averageDailyVolume10Day": 499559, "bid": 4.45, "ask": 4.8, "bidSize": 900, "askSize": 1000, "marketCap": 2891375, "fiftyTwoWeekLow": 4.05, "fiftyTwoWeekHigh": 92.62, "fiftyDayAverage": 6.56072, "twoHundredDayAverage": 22.14418, "currency": "USD", "enterpriseValue": -7933619, "floatShares": 489732, "sharesOutstanding": 533464, "sharesShort": 3496, "sharesShortPriorMonth": 380, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0069, "heldPercentInsiders": 0.00765, "heldPercentInstitutions": 0.08297, "shortRatio": 0.39, "shortPercentOfFloat": 0.0069, "impliedSharesOutstanding": 633986, "bookValue": 27.621, "priceToBook": 0.1962275, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -18650000, "trailingEps": -67.07, "forwardEps": -10.5, "lastSplitFactor": "1:44", "lastSplitDate": 1709683200, "enterpriseToEbitda": 0.28, "52WeekChange": -0.9300103, "SandP52WeekChange": 0.29495108, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "APVO", "underlyingSymbol": "APVO", "shortName": "Aptevo Therapeutics Inc.", "longName": "Aptevo Therapeutics Inc.", "firstTradeDateEpochUtc": 1469021400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "470316e1-b879-3a10-830d-ae029cd54a71", "messageBoardId": "finmb_331280020", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.42, "targetHighPrice": 440.0, "targetLowPrice": 10.5, "targetMeanPrice": 225.25, "targetMedianPrice": 225.25, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 16904000, "totalCashPerShare": 31.687, "ebitda": -28311000, "totalDebt": 6079000, "quickRatio": 2.34, "currentRatio": 2.639, "debtToEquity": 49.742, "returnOnAssets": -0.61123, "returnOnEquity": -1.2353, "freeCashflow": -12378750, "operatingCashflow": -11730000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-17"}]